TY - JOUR
T1 - Report of A Family with Adult-Onset Leukoencephalopathy with Axonal Spheroids and Pigmented Glia (ALSP) Without Mutations in CSF1R, AARS1 or AARS2
AU - Dulski, Jarosław
AU - Koga, Shunsuke
AU - Dickson, Dennis W.
AU - Wszolek, Zbigniew K.
N1 - Funding Information:
Jaroslaw Dulski: Employment: Medical University of Gdansk, Copernicus PL Ltd., MJ Jarosław Dulski; Honoraria: VM Media Ltd., Radosław Lipiński 90 Consulting, Ipsen; Grants: the Haworth Family Professorship in Neurodegenerative Diseases fund, the Polish National Agency for Academic Exchange (BPN/WAL/2022/1/00007/U/00001); Shunsuke Koga: Grants: Mayo Clinic Alzheimer's Disease Research Center Research Grant; The State of Florida Ed and Ethel Moore Alzheimer's Disease Research Fellowship Grant; Dennis W. Dickson: Employment: Mayo Clinic; Grants: NIH P30 AG062677, U19 AG063911; Zbigniew K. Wszolek: Intellectual Property Rights: Mayo Clinic and ZKW have a financial interest in technologies entitled, “Identification of Mutations in PARK8, a Locus for Familial Parkinson's Disease” and “Identification of a Novel LRRK2 Mutation, 6055G>A (G2019S), Linked to Autosomal Dominant Parkinsonism in Families from Several European Populations”. Those technologies have been licensed to a commercial entity, and to date, ZKW has received royalties <$1500 through Mayo Clinic in accordance with its royalty sharing policies; Consultancies: Vigil Neuroscience, Inc; Advisory Boards: Vigil Neuroscience, Inc; Employment: Mayo Clinic Florida; Honoraria: Polish Neurological Society—co‐editor‐in‐chief of Neurologia i Neurochirurgia Polska; Grants: NIH/NIA and NIH/NINDS (1U19AG063911, FAIN: U19AG063911), Mayo Clinic Center for Regenerative Medicine, Mayo Clinic in Florida Focused Research Team Program, the gifts from the Donald G. and Jodi P. Heeringa Family, the Haworth Family Professorship in Neurodegenerative Diseases fund, and The Albertson Parkinson's Research Foundation. He serves as PI or Co‐PI on Biohaven Pharmaceuticals, Inc. (BHV4157‐206 and BHV3241‐301), Neuraly, Inc. (NLY01‐PD‐1), and Vigil Neuroscience, Inc. (VGL101‐01.001) grants. Financial Disclosures for the Previous 12 Months:
Publisher Copyright:
© 2022 International Parkinson and Movement Disorder Society.
PY - 2023/2
Y1 - 2023/2
N2 - Background: Adult-onset leukoencephalopathy with axonal spheroids and pigmented glia (ALSP) is a rare neurodegenerative disorder with characteristic clinicopathological features. Identification of pathogenic mutations in CSF1R, AARS1, and AARS2 genes led to increased recognition and diagnosis of the ALSP. Objectives: This paper presents the first family with typical clinical, radiological, and pathological features of ALSP, yet negative for CSF1R, AARS1, and AARS2 mutations. Methods: The index case was a 30-year-old male who presented with gait difficulty, followed by cognitive decline and incontinence. Results: Neurological examination evidenced progressive dementia, dysarthria, spasticity, parkinsonism, and severe gait disturbances. Brain MRI showed confluent white matter abnormalities with scattered foci of restricted diffusion, and atrophy of the corpus callosum. He was suspected of ALSP; however, the extensive genetic work-up did not find pathogenic mutation. He died at 33 years, and brain autopsy was performed. He had myelin staining pallor and axonal swellings, spheroids, and pigmented glia in affected white matter. His father developed similar symptoms in his early 40s and died at 46 years. Neuropathological examination also confirmed ALSP diagnosis. We found two similar cases in the literature with typical ALSP features but negative for CSF1R mutation; however, none were tested for AARS1 and AARS2 mutations. Conclusions: We draw attention to a new entity within the ALSP disease spectrum that needs further investigation. As the disease-modifying therapy is already available for ALSP-CSF1R, there is a strong need to identify the genetic cause of patients such as these in the ALSP spectrum, enabling research toward implementing effective treatment.
AB - Background: Adult-onset leukoencephalopathy with axonal spheroids and pigmented glia (ALSP) is a rare neurodegenerative disorder with characteristic clinicopathological features. Identification of pathogenic mutations in CSF1R, AARS1, and AARS2 genes led to increased recognition and diagnosis of the ALSP. Objectives: This paper presents the first family with typical clinical, radiological, and pathological features of ALSP, yet negative for CSF1R, AARS1, and AARS2 mutations. Methods: The index case was a 30-year-old male who presented with gait difficulty, followed by cognitive decline and incontinence. Results: Neurological examination evidenced progressive dementia, dysarthria, spasticity, parkinsonism, and severe gait disturbances. Brain MRI showed confluent white matter abnormalities with scattered foci of restricted diffusion, and atrophy of the corpus callosum. He was suspected of ALSP; however, the extensive genetic work-up did not find pathogenic mutation. He died at 33 years, and brain autopsy was performed. He had myelin staining pallor and axonal swellings, spheroids, and pigmented glia in affected white matter. His father developed similar symptoms in his early 40s and died at 46 years. Neuropathological examination also confirmed ALSP diagnosis. We found two similar cases in the literature with typical ALSP features but negative for CSF1R mutation; however, none were tested for AARS1 and AARS2 mutations. Conclusions: We draw attention to a new entity within the ALSP disease spectrum that needs further investigation. As the disease-modifying therapy is already available for ALSP-CSF1R, there is a strong need to identify the genetic cause of patients such as these in the ALSP spectrum, enabling research toward implementing effective treatment.
KW - dementia
KW - gait
KW - neurodegenerative
KW - parkinsonism
KW - spasticity
UR - http://www.scopus.com/inward/record.url?scp=85146182579&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85146182579&partnerID=8YFLogxK
U2 - 10.1002/mdc3.13650
DO - 10.1002/mdc3.13650
M3 - Article
AN - SCOPUS:85146182579
SN - 2330-1619
VL - 10
SP - 307
EP - 312
JO - Movement Disorders Clinical Practice
JF - Movement Disorders Clinical Practice
IS - 2
ER -